213 related articles for article (PubMed ID: 26377238)
1. Oxaliplatin immuno hybrid nanoparticles for active targeting: an approach for enhanced apoptotic activity and drug delivery to colorectal tumors.
Tummala S; Gowthamarajan K; Satish Kumar MN; Wadhwani A
Drug Deliv; 2016 Jun; 23(5):1773-87. PubMed ID: 26377238
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin immunohybrid nanoparticles in vitro synergistic suppression evaluation in treatment of colorectal cancer.
Tummala S; Gowthamarajan K; Satish Kumar MN
Artif Cells Nanomed Biotechnol; 2017 Mar; 45(2):261-269. PubMed ID: 26933919
[TBL] [Abstract][Full Text] [Related]
3. Improved anti-tumor activity of oxaliplatin by encapsulating in anti-DR5 targeted gold nanoparticles.
Tummala S; Kumar MN; Pindiprolu SK
Drug Deliv; 2016 Nov; 23(9):3505-3519. PubMed ID: 27295176
[TBL] [Abstract][Full Text] [Related]
4. Formulation and optimization of oxaliplatin immuno-nanoparticles using Box-Behnken design and cytotoxicity assessment for synergistic and receptor-mediated targeting in the treatment of colorectal cancer.
Tummala S; Gowthamarajan K; Satish Kumar MN; Praveen TK; Yamjala K; Tripuraneni NS; Prakash A
Artif Cells Nanomed Biotechnol; 2016 Dec; 44(8):1835-1850. PubMed ID: 26697734
[TBL] [Abstract][Full Text] [Related]
5. Engineering of caveolae-specific self-micellizing anticancer lipid nanoparticles to enhance the chemotherapeutic efficacy of oxaliplatin in colorectal cancer cells.
Sundaramoorthy P; Ramasamy T; Mishra SK; Jeong KY; Yong CS; Kim JO; Kim HM
Acta Biomater; 2016 Sep; 42():220-231. PubMed ID: 27395829
[TBL] [Abstract][Full Text] [Related]
6. 5-Fluorouracil enteric-coated nanoparticles for improved apoptotic activity and therapeutic index in treating colorectal cancer.
Tummala S; Kuppusamy G; Satish Kumar MN; Praveen TK; Wadhwani A
Drug Deliv; 2016 Oct; 23(8):2902-2910. PubMed ID: 26634385
[TBL] [Abstract][Full Text] [Related]
7. Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer.
Min SY; Byeon HJ; Lee C; Seo J; Lee ES; Shin BS; Choi HG; Lee KC; Youn YS
Int J Pharm; 2015 Oct; 494(1):506-15. PubMed ID: 26315118
[TBL] [Abstract][Full Text] [Related]
8. Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer.
Jain A; Jain SK; Ganesh N; Barve J; Beg AM
Nanomedicine; 2010 Feb; 6(1):179-90. PubMed ID: 19447205
[TBL] [Abstract][Full Text] [Related]
9. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
[TBL] [Abstract][Full Text] [Related]
10. Colorectal cancer-targeted delivery of oxaliplatin via folic acid-grafted solid lipid nanoparticles: preparation, optimization, and in vitro evaluation.
Rajpoot K; Jain SK
Artif Cells Nanomed Biotechnol; 2018 Sep; 46(6):1236-1247. PubMed ID: 28849671
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin-chitosan nanoparticles induced intrinsic apoptotic signaling pathway: a "smart" drug delivery system to breast cancer cell therapy.
Vivek R; Thangam R; Nipunbabu V; Ponraj T; Kannan S
Int J Biol Macromol; 2014 Apr; 65():289-97. PubMed ID: 24472507
[TBL] [Abstract][Full Text] [Related]
13. Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles.
Lim SM; Kim TH; Jiang HH; Park CW; Lee S; Chen X; Lee KC
Biomaterials; 2011 May; 32(13):3538-46. PubMed ID: 21306770
[TBL] [Abstract][Full Text] [Related]
14. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.
Lee AL; Dhillon SH; Wang Y; Pervaiz S; Fan W; Yang YY
Mol Biosyst; 2011 May; 7(5):1512-22. PubMed ID: 21350763
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.
El Fajoui Z; Toscano F; Jacquemin G; Abello J; Scoazec JY; Micheau O; Saurin JC
Gastroenterology; 2011 Aug; 141(2):663-73. PubMed ID: 21683075
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer.
Wang K; Liu L; Zhang T; Zhu YL; Qiu F; Wu XG; Wang XL; Hu FQ; Huang J
Int J Nanomedicine; 2011; 6():3207-18. PubMed ID: 22238509
[TBL] [Abstract][Full Text] [Related]
17. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
18. Layer by layer assembly of albumin nanoparticles with selective recognition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Cui W; Wang A; Zhao J; Yang X; Cai P; Li J
J Colloid Interface Sci; 2016 Mar; 465():11-7. PubMed ID: 26641559
[TBL] [Abstract][Full Text] [Related]
19. PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma.
Yang C; Liu HZ; Lu WD; Fu ZX
Oncol Rep; 2011 Jun; 25(6):1621-8. PubMed ID: 21455585
[TBL] [Abstract][Full Text] [Related]
20. Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides.
Hong ST; Lin H; Wang CS; Chang CH; Lin AM; Yang JC; Lo YL
J Nanobiotechnology; 2019 Aug; 17(1):89. PubMed ID: 31426807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
